Clinician feedback using a shared decision-making tool for the evaluation of patients with thyroid nodules-an observational study

BACKGROUND

We pilot-tested an encounter conversation aid to support shared decision making (SDM) between patients with thyroid nodules and their clinicians.

OBJECTIVE

Characterize the clinician feedback after providing care to patients with thyroid nodules using a tool to promote SDM conversations during the clinical encounter, and evaluate how clinicians used the tool during the visit.

METHODS

Mixed method study in two academic centers in the U.S., including adult patients presenting for evaluation of thyroid nodules and their clinicians. We thematically analyzed interviews with clinicians after they used the SDM tool in at least three visits to characterize their feedback. Additionally, investigators evaluated visits recordings to determine the extent to which clinicians engaged patients in the decision-making process (OPTION score, scale 0 to 100, higher levels indicating higher involvement), the tool's components used (fidelity), and encounter duration. Using a post-visit survey, we evaluated the extent to which clinicians felt the tool was easy to use, helpful, and supportive of the patient-clinician collaboration.

RESULTS

Thirteen clinicians participated in the study and used the SDM tool in the care of 53 patients. Clinicians thought the tool was well-organized and beneficial to patients and clinicians. Clinicians noticed a change in their routine with the use of the conversation aid and suggested it needed to be more flexible to better support varying conversations. The median OPTION score was 34, the fidelity of use 75%, and the median visit duration 17 min. In most encounters, clinicians agreed or strongly agreed the tool was easy to use (86%), helpful (65%), and supported collaboration (62%).

CONCLUSION

Clinicians were able to use a SDM tool in the care of patients with thyroid nodules. Although they wished it were more flexible, they found on the whole that its use in the clinical encounter was beneficial to patients and clinicians.

ODP131 Zoledronic acid and red eye

Introduction

Zoledronic acid, used for treatment of osteoporosis, Paget's disease of the bone, hypercalcemia of malignancy etc. is a bisphosphonate known for its anti-resorptive effect. A common adverse reaction with this medication is mild to moderate flu-like symptoms, which is transient and attributed to an acute phase reaction post zoledronic acid infusion. [1] A less common adverse reaction is ocular inflammation, including uveitis, iritis and episcleritis. [1] The incidence of ocular inflammation is 0.2 - 0.8%. [2] Development of ocular symptoms have been reported to occur between 1 to 7 days post zoledronic acid infusion. [2] We report a case of acute unilateral episcleritis following zoledronic acid infusion for treatment of osteoporosis. Clinical case: A 58-year-old female with a past medical history significant for glaucoma and gastroesophageal reflux (GERD) presented for management of osteoporosis. She could not tolerate oral bisphosphonates due to gastrointestinal side effects. She was therefore switched to intravenous zoledronic acid therapy. On day 1 post zoledronic acid infusion of 5mg dose, she developed diffuse joint and muscle pain as well as right eye pain, redness, photophobia, blurred vision and tearing. As her ocular symptoms progressed by day 5 post zoledronic acid infusion, she presented urgently to ophthalmology clinic when she was diagnosed with episcleritis of the right eye secondary to the zoledronic acid infusion. Patient was started on prednisolone acetate eyedrops twice a day. Three days after starting the eyedrops, patient reported complete resolution of her ocular symptoms. Further treatment for osteoporosis with zoledronic acid was discontinued.

Conclusion

We present a case of right eye episcleritis occurring 24 hours post zoledronic acid infusion leading to significant ocular discomfort and concern for the patient. Ocular inflammation is an uncommon occurrence post zoledronic acid infusion, hence is not often discussed during routine patient counseling in regards to risks and benefits of this particular treatment. We therefore stress the need for both provider and patient awareness regarding this uncommon ocular side effect related to zoledronic acid use. It is important to inform the patient and educate providers about the possibility of this acute phase reaction occurring post treatment with zoledronic acid to aid in prompt diagnosis and treatment. Our patient responded well to treatment with prednisolone acetate ophthalmologic drops. A rechallenge with zoledronic acid has not been pursued. References: 1. Jin X, Shou Z, Shao Y, Bian P. Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature. Arch Osteoporos.2021;16(1): 104. Published 2021 Jun 28. doi: 10.1007/s11657-021-00964-z 2. Patel DV, Horne A, House M, Reid IR, McGhee CN. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013 Apr;120(4): 773-6. doi: 10.1016/j. ophtha.2012.10. 028. Epub 2013 Jan 3. PMID: 23290982

Presentation: No date and time listed

PSAT245 Feasibility of introducing a conversation aid for patients with thyroid nodules in clinical practice: Understanding the clinician experience

Background

To support the collaboration between patients with thyroid nodules and their clinician, we developed a Thyroid NOdule conversation aid (TNOC). TNOC includes a representation of thyroid cancer risk, alternative management options, and a print-out summary for patients. In a pilot study, the use of TNOC was associated with improvement in the quality of diagnostic conversations.

Research question: The aim of this study was to evaluate the feasibility of introducing TNOC into clinical encounters and understand clinicians’ experience with its use.

Methods

Prospective study conducted in two academic centers in the U.S. We included adult patients with thyroid nodules and their clinicians (endocrinologists and ear, nose, and throat specialists (ENT)). The feasibility of introducing TNOC was evaluated by the fidelity to which TNOC was used (12 item checklist of included components, such as: thyroid cancer risk presentation, management options) and the duration of clinical visits, evaluated through video recordings. Clinicians completed a post-visit survey to evaluate how helpful and easy to use TNOC was and the degree to which it supported collaboration with their patients. A qualitative analysis of semi-structured interviews was conducted after clinicians used TNOC in at least three visits. The interview guide was developed following constructs included in the Consolidated Framework for Implementation Research. Analysis was conducted using the constant comparative method.

Results

Twelve clinicians (9 endocrinologists and 3 ENT) were included and used TNOC with 53 patients. Most patients were women (N -42, 79%) with a median age of 62 years (Interquartile range, 53-70). The median size of the thyroid nodules was 2.3 cm (Interquartile range, 1.3, 3.0). The median clinical visit duration was 17 minutes (Interquartile range 10,28). The median fidelity score was 75% (interquartile range 58, 75), with thyroid cancer risk presentation being the most commonly used item (98%) and the printable summary the least used (15%). Clinicians agreed or strongly agreed that TNOC was helpful (N=34, 65%), easy to use (N=44, 85%), and supported collaboration with patients (N= 32, 62%).

In the qualitative analysis, clinicians reported that TNOC was organized and covered commonly discussed topics. Moreover, the use of TNOC could support the clinical interaction and be beneficial for patients by assuring the patient perspective was considered, creating space for questions, and improving how information was presented. Yet, the perceived benefit of using TNOC was expected to be different depending on the expertise of the clinician, as experts might benefit less. Clinicians highlighted the importance of familiarity with TNOC to ease its use and suggested modifications: additional visual content, improved navigation to support dynamic use and providing patient access before/after the visit.

Interpretation: Using TNOC to support thyroid nodule management conversations was feasible, helpful, easy to use, and supportive of patient-clinician collaboration.

Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.

PSAT246 Decision Making for Patients with Thyroid Nodules: Understanding the Patient's Experience

Background

We recently developed a Thyroid NOdule conversation aid (TNOC), a conversation tool that supports communication about management options between patients with thyroid nodules and their clinicians. TNOC uses an interactive electronic interface to support conversations about thyroid cancer risk in patients with thyroid nodules and management options. In a pilot study, the use of TNOC in the clinical encounter was associated with improvement in the quality of diagnostic conversations.

Research question: The aim of the study was to evaluate the patient's experience when receiving care using TNOC.

Methods

Prospective study conducted in two academic centers in the U.S. We included adult patients presenting for the evaluation of thyroid nodules and using TNOC in the encounters with their clinicians. Patients that were hyperthyroid, pregnant or had records of previous biopsy were excluded. Patient demographics and clinical features were obtained through electronic health record review. We conducted post-visit semi-structured interviews to assess patients’ experiences using TNOC. The semi-structured interview was developed following constructs included in the Consolidated Framework for Implementation Research. Qualitative analysis was conducted following the constant comparative method to identify emerging themes related to the patient experiences using TNOC. After an initial group of themes were identified, a final set of themes was derived based on prevalence and salience, following an iterative process by two coders.

Results

53 patients were enrolled in the study and 49 completed the post-visit interview. Most patients were women (N -42, 79%) and white (N-47, 89%) with a median age of 62 years (Interquartile range, 53-70). The median size of the thyroid nodules was 2.3 cm (Interquartile range, 1.3, 3.0) and 45% were ACR-TIRADS 4 or 5 (N-24). Most nodules were found incidentally (N-37, 70%).

In the qualitative assessment, the layman terms included in TNOC, the structured, step-wise and visual presentation of information were considered positively by patients. The language, visuals, and structure of TNOC supported knowledge transfer about thyroid nodules and their management options, helping them better understand their situation. Patients felt they worked together with their clinician by going through the conversation aid, making them feel comfortable asking questions. However, patients reported that the clinician's familiarity with TNOC and the learning needs of patients could affect the perceived benefit of the conversation aid. Patients suggested including more information and visuals in TNOC and providing access before/after the visit.

Interpretation: Patients found that the use of TNOC in medical encounters was helpful to understand information, treatment options, and working with their clinicians. This information supports the implementation of TNOC in practice to support decision-making.

Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.

Evaluation of multinodular goiter and primary hyperparathyroidism leads to a diagnosis of AL amyloidosis

Background

Amyloid goiter, defined as excess amyloid within the thyroid gland in such quantities that it produces a clinically apparent goiter, is a very rare manifestation of systemic amyloidosis with cases commonly seen in the setting of Amyloid A (AA) amyloidosis. Amyloid goiter as the primary clinical manifestation secondary to Amyloid light chain (AL) amyloidosis is very rare. We present a case of AL amyloidosis with initial manifestation as goiter with amyloid deposition in the thyroid and the parathyroid gland.

Case Presentation

A 73 year old male presented with goiter and compressive symptoms of dysphagia and hoarseness. Laboratory workup revealed normal thyroid function, nephrotic range proteinuria, elevated serum calcium level with an elevated parathyroid hormone level (PTH) consistent with primary hyperparathyroidism. Thyroid ultrasound showed an asymmetric goiter with three dominant nodules. Cervical computed tomography revealed a goiter with substernal extension and deviation of the trachea. Fine needle aspiration was unsatisfactory. There was also evidence of osteoporosis and hypercalciuria with negative Sestamibi scan for parathyroid adenoma. The patient underwent a total thyroidectomy and one gland parathyroidectomy. Pathology revealed benign thyroid parenchyma with diffuse amyloid deposition in the thyroid and parathyroid gland that stained apple green birefringence under polarized light on Congo Red stain. Immunochemical staining detected AL amyloid deposition of the lambda type. Bone marrow biopsy revealed an excess monoclonal lambda light chain of plasma cells consistent with a diagnosis of AL amyloidosis secondary to multiple myeloma affecting the kidney, thyroid, parathyroid gland, and heart. He was treated with 4 cycles of chemotherapy with a decrease in the M spike and light chains with a plan to pursue a bone marrow transplant.

Conclusion

Amyloid goiter as the primary clinical manifestation secondary to AL amyloidosis with deposition in the thyroid and parathyroid gland is rare. The top differential for amyloid deposits in the thyroid includes systemic amyloidosis or medullary thyroid carcinoma. The definitive diagnosis lies in the histopathology of the thyroid tissue. To diagnose systemic amyloidosis as the etiology for a goiter, a solid understanding of the causes of systemic amyloidosis coupled with a thorough evaluation of the patient’s history and laboratory data is necessary.

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

CONTEXT

The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in the United States. This calls for greater awareness among endocrinologists, who often see but may miss the diagnosis in adults with obesity or type 2 diabetes mellitus (T2D) who are at the highest risk. At the same time, recent studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are beneficial vs nonalcoholic steatohepatitis (NASH) in this population. This minireview aims to assist endocrinologists to recognize the condition and recent work on the role of GLP-1RAs in NAFLD/NASH.

EVIDENCE ACQUISITION

Evidence from observational studies, randomized controlled trials, and meta-analyses.

EVIDENCE SYNTHESIS

Endocrinologists should lead multidisciplinary teams to implement recent consensus statements on NAFLD that call for screening and treatment of clinically significant fibrosis to prevent cirrhosis, especially in the high-risk groups (ie, people with obesity, prediabetes, or T2D). With no US Food and Drug Administration (FDA)-approved agents, weight loss is central to successful management, with pharmacological treatment options limited today to vitamin E (in people without T2D) and diabetes medications that reverse steatohepatitis, such as pioglitazone or GLP-1RA. Recently, the benefit of GLP-1RAs in NAFLD, suggested from earlier trials, has been confirmed in adults with biopsy-proven NASH. In 2021, the FDA also approved semaglutide for obesity management.

CONCLUSION

A paradigm change is developing between the endocrinologist's greater awareness about their critical role to curve the epidemic of NAFLD and new clinical care pathways that include a broader use of GLP-1RAs in the management of these complex patients.